Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(11%)
Results Posted
67%(4 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_3
1
11%
Ph phase_1
4
44%
Ph phase_2
4
44%

Phase Distribution

4

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 24 (44.4%)
Phase 31 (11.1%)

Trials by Status

completed667%
terminated222%
active_not_recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruitingphase_2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
terminatedphase_3

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
terminatedphase_2

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

NCT03059446
completedphase_2

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828
completedphase_2

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting
NCT03028740Phase 3

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Terminated
NCT03059446Phase 2

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Terminated
NCT02128828Phase 2

Effect of Cenicriviroc on HIV Neurocognitive Impairment

Completed
NCT02217475Phase 2

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Completed
NCT03376841Phase 1

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Completed
NCT02684799Phase 1

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Completed
NCT02342067Phase 1

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Completed
NCT01827540Phase 1

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9